Clinical trial
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in…
NCT00150462 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00150462 |
|---|---|
| Title | Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies |
| Official title | A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Waldenstrom's Macroglobulinemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Carfilzomib, Dexamethasone |
| Enrollment | 48 |
| Start date | Sep 1, 2005 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Sep 8, 2005 |
| Last update posted | May 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: